Stem Cell Research Lands TheraVitae CEO in Top 100 List

Stem Cell Company CEO Valentin Fulga one of Israel's 100 most important people.

Tel Aviv (PRWEB) September 28, 2005 -- TheraVitae CEO, Dr. Valentin Fulga was named one of Israels 100 Most Important People" by The Marker magazine. Dr. Fulga was named the 8th most important executive in the category of International Influence."

Dr. Fulga was honored with the nomination for his role in leading TheraVitae to breakthroughs in autologous stem cell research and therapy. Currently, TheraVitaes first commercial product, VesCell is being used to treat a variety of heart disorders.

Speaking to The Marker, Fulga said, "The treatment is still in its early stages, but the results are so positive that there is no reason why it should not become more and more widespread. Regarding future developments - I must be cautious, but will say that we may have discovered a blood-derived cell population which has the potential to become many different types of cells, not only blood vessel-generating cells. The therapeutic implications of this are amazing. If things progress the way we expect, in ten years, or perhaps even less, we will draw half a liter of blood and will be able to treat a wide variety of diseases."

Also recognized in the article was Dr. Yael Porat, TheraVitaes Senior Director of Research and Development.

About VesCell
VesCell consists of a patients own adult stem cells harvested from approximately ½ pint of the patients own blood and is used to treat heart disorders. Once harvested, the cells are expanded and differentiated in vitro at the TheraVitae laboratories in Israel and are ready for implantation in about one week. The cellular product is a viable alternative for patients who either cannot undergo or choose not to undergo the standard revascularization treatments.
http://www.vescell.com/fulga.html

About TheraVitae
TheraVitae is a private, multinational company focused on using stem cells from the patient's own blood in order to treat a variety of disorders, especially cardiovascular diseases. The company has developed a proprietary stem cell technology called VesCell that is currently being used by hospitals in Thailand to treat patients with heart disease. TheraVitae is based in Bangkok, Thailand, Kiryat Weizmann, Israel, and Hong Kong. http://www.theravitae.com.

TheraVitae, Ltd.
36/72 PS Tower, 21/Fl.,
Sukhumvit 21, Klongtoey Nua,
Bangkok 10110
Thailand

###